Waheed Nadia, Saeed Anjum, Ijaz Sadaqat, Fayyaz Zafar, Anjum Muhammad Nadeem, Zahoor Yasir, Cheema Huma Arshad
Department of Pediatric Medicine, Division of Pediatric Gastroenterology, Hepatology & Nutrition, The Children's Hospital & Institute of Child Health, Lahore, Pakistan.
J Pediatr Endocrinol Metab. 2020 Sep 25;33(9):1117-1123. doi: 10.1515/jpem-2019-0603.
Background PHKG2-related liver phosphorylase kinase deficiency is inherited in autosomal recessive pattern and is a rare type of liver glycogenosis. We demonstrated the clinical presentation and genetic determinants involved in children with PHKG2- related liver phosphorylase kinase deficiency. Methodology Ten Pakistani children with liver phosphorylase kinase from seven different families, were enrolled over a period of 18 months. All regions of the PHKG2 gene spanning exons and splicing sites were evaluated through targeted exome sequencing. Variants were analyzed using different bioinformatics tools. Novel variants were reconfirmed by direct sequencing. Results Seven different variants were identified in PHKG2 gene including five novel variants: three stop codons (c.226C>T [p.R76*], c.454C>T [p.R152*] and c.958C>T [p.R320*]), one missense variant c.107C>T (p.S36F) and one splice site variant (c.557-3C>G). All five novel variants were predicted to be damaging by in Silico analysis. The variants are being transmitted through recessive pattern of inheritance except one family (two siblings) has compound heterozygotes. Laboratory data revealed elevated transaminases and triglycerides, normal creatinine phosphokinase and uric acid levels but with glycogen loaded hepatocytes on liver histology. Conclusion PHKG2 related liver phosphorylase kinase deficiency can mimic both liver glycogenosis type I (glucose-6-phosphatase deficiency) & III(amylo-1,6 glucosidase) and characterized by early childhood onset of hepatomegaly, growth restriction, elevated liver enzymes and triglycerides. Molecular analysis would be helpful in accurate diagnosis and proper treatment. The symptoms and biochemical abnormalities in liver glycogenosis due phosphorylase kinase deficiency tend to improve with proper dietary restrictions but need to be monitored for long-term complications such as liver fibrosis and cirrhosis.
PHKG2相关的肝磷酸化酶激酶缺乏症以常染色体隐性模式遗传,是一种罕见的肝糖原贮积症类型。我们阐述了PHKG2相关的肝磷酸化酶激酶缺乏症患儿的临床表现和遗传决定因素。方法:在18个月的时间里,招募了来自7个不同家庭的10名患有肝磷酸化酶激酶缺乏症的巴基斯坦儿童。通过靶向外显子组测序评估PHKG2基因跨越外显子和剪接位点的所有区域。使用不同的生物信息学工具分析变异体。通过直接测序再次确认新变异体。结果:在PHKG2基因中鉴定出7种不同的变异体,包括5种新变异体:3个终止密码子(c.226C>T [p.R76*]、c.454C>T [p.R152*]和c.958C>T [p.R320*])、1个错义变异体c.107C>T(p.S36F)和1个剪接位点变异体(c.557-3C>G)。通过计算机分析预测,所有5种新变异体均具有损害性。除了一个家庭(两名兄弟姐妹)为复合杂合子外,这些变异体均通过隐性遗传模式传递。实验室数据显示转氨酶和甘油三酯升高,肌酸磷酸激酶和尿酸水平正常,但肝脏组织学检查显示肝细胞内有糖原沉积。结论:PHKG2相关的肝磷酸化酶激酶缺乏症可类似I型肝糖原贮积症(葡萄糖-6-磷酸酶缺乏症)和III型(淀粉-1,6-葡萄糖苷酶缺乏症),其特征为儿童早期出现肝肿大、生长受限、肝酶和甘油三酯升高。分子分析有助于准确诊断和恰当治疗。由于磷酸化酶激酶缺乏导致的肝糖原贮积症的症状和生化异常在适当的饮食限制下往往会改善,但需要监测长期并发症,如肝纤维化和肝硬化。